Research Analysts Offer Predictions for USNA FY2026 Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Analysts at Sidoti boosted their FY2026 earnings per share (EPS) estimates for shares of USANA Health Sciences in a research note issued to investors on Thursday, February 19th. Sidoti analyst A. Lebiedzinski now expects that the company will post earnings per share of $2.00 for the year, up from their prior forecast of $1.84. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti also issued estimates for USANA Health Sciences’ Q4 2026 earnings at $0.66 EPS.

Several other brokerages have also recently commented on USNA. Wall Street Zen raised shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research report on Saturday. Zacks Research upgraded USANA Health Sciences from a “strong sell” rating to a “hold” rating in a report on Monday, February 16th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, December 29th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, USANA Health Sciences has an average rating of “Reduce” and an average target price of $36.00.

USANA Health Sciences Stock Performance

Shares of USNA stock opened at $21.69 on Monday. USANA Health Sciences has a fifty-two week low of $18.48 and a fifty-two week high of $38.32. The company has a 50 day moving average price of $20.71 and a 200 day moving average price of $23.45. The stock has a market capitalization of $396.46 million, a P/E ratio of 39.43, a price-to-earnings-growth ratio of 0.90 and a beta of 0.67.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.19. USANA Health Sciences had a net margin of 1.16% and a return on equity of 6.75%. The company had revenue of $226.20 million for the quarter, compared to analyst estimates of $225.96 million.

Institutional Trading of USANA Health Sciences

Several institutional investors have recently modified their holdings of USNA. Pzena Investment Management LLC grew its position in shares of USANA Health Sciences by 1.2% in the 3rd quarter. Pzena Investment Management LLC now owns 1,212,588 shares of the company’s stock valued at $33,407,000 after buying an additional 14,328 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of USANA Health Sciences by 1.9% during the fourth quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company’s stock worth $22,522,000 after purchasing an additional 21,793 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of USANA Health Sciences by 5.7% during the third quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock worth $29,452,000 after purchasing an additional 57,249 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of USANA Health Sciences by 1.9% during the third quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company’s stock worth $25,210,000 after purchasing an additional 17,318 shares in the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in shares of USANA Health Sciences in the 4th quarter valued at about $11,485,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.